

Placebo group
Telitacicept 160 mg group
Telitacicept 240 mg group
Changes of glomerular filtration rate (mL/min/1.73^2)
20
10
0
-10
-20
0wk
8wk
16wk
24wk
Visit (weeks)

FIG.1



Placebo group
Telitacicept 160 mg group
Telitacicept 240 mg group
Changes of urine albumin/creatinine ratio (mg/mmol)
1000
500
0
-500
-1000
0wk
8wk
16wk
24wk
Visit (weeks)

FIG.2



Placebo group
Telitacicept 160 mg group
Telitacicept 240 mg group
Changes of urine red blood cell (/HP)
75
50
25
0
-25
-50
0wk
8wk
16wk
24wk
Visit (weeks)

FIG.3



Placebo group
Telitacicept 160 mg group
Telitacicept 240 mg group
Changes of IgA (g/L)
2
1
0
-1
-2
-3
*
0wk
8wk
16wk
24wk
Visit (weeks)

FIG.4



Placebo group
Telitacicept 160 mg group
Telitacicept 240 mg group
Changes of IgG (g/L)
2
0
-2
-4
-6
0wk
8wk
16wk
24wk
Visit (weeks)

FIG.5



Placebo group
Telitacicept 160 mg group
Telitacicept 240 mg group
Changes of IgM (g/L)
1.5
1.0
0.5
0.0
-0.5
-1.0
-1.5
0wk
8wk
16wk
24wk
Visit (weeks)

FIG.6



Placebo group
Telitacicept 160 mg group
Telitacicept 240 mg group
Changes of B lymphocyte count (/μL)
200
100
0
-100
-200
-300
*
*
0wk
8wk
16wk
24wk
Visit (weeks)

FIG.7